NanoPhoria is a preclinical stage biotech company pioneering inhalable cardiovascular treatments via non-viral nano-delivery of biologics.
The Company is devoted to the clinical development of an innovative proprietary platform for the tissue-directed delivery of therapeutic peptides and RNAs. The core vehicle is an inorganic calcium-phosphate nanoparticle
which represents a versatile, biomimetic nano-carrier that can be loaded or surface decorated with biologics and can be formulated for inhalation or for other administration routes.
NanoPhoria’s lead product, NP-MP1 is an inhalable nano-in-micro formulation, delivering a proprietary peptide, first-in-class calcium channel modulator, for the treatment of Heart Failure with reduced Ejection Fraction, a chronic syndrome affecting the lives of millions worldwide.
Company Details
- Employees
- 6
- Founded
- 2022
- Address
- Via Borgogna, 5, Milan,lombardy 20122,italy
- Industry
- Biotechnology
- Website
- http://www.nanophoria.com
- Keywords
- Finceramica.
- HQ
- Milan, Lombardy
Nanophoria Questions
Nanophoria's website is http://www.nanophoria.com
Nanophoria's LinkedIn profile is https://it.linkedin.com/company/nanophoria
Nanophoria has
6 employees.
View email and phone details for 6
employees at Nanophoria.
Nanophoria's industry is
Biotechnology
Nanophoria's top competitors are
Aera Therapeutics,
Nanomnia,
Aindo,
Accelera,
Bioinspiresensing,
Finceramica,
Technopharmasphere,
Nanovation Therapeutics™,
Startric,
Orion Therapeutics, Inc..
Nanophoria's categories are Biotechnology
Nanophoria's founding year is 2022
